Evonik Boosts Lipid-Based Drug Delivery in Vancouver

Evonik Industries AG is set to enhance its lipid-based drug delivery capabilities with a new GMP manufacturing facility in Vancouver, Canada. The initiative involves an investment of over 150 million CAD, partially supported by the Canadian federal government's Strategic Response Fund with up to 68 million CAD. Production is expected to commence at the end of 2029.

This expansion significantly increases Evonik's capacity, more than tripling current capabilities. It also advances quality control and testing, ensuring timely product releases. The move aligns with Evonik's ongoing efforts in lipid-based drug delivery, a field crucial for the development of vaccines and advanced medicines.

The Vancouver facility strengthens Evonik's global network, which includes sites in the USA and Germany, all focused on lipid and LNP formulation development and manufacturing. The LNP market, integral to nucleic acid-based drugs, is projected to reach $2.7 billion by 2034, highlighting the growing demand.